- £81.91bn
- £95.80bn
- £32.67bn
REG - GlaxoSK Capital PLC GSK PLC - Publication of EMTN Supplementary Prospectus
AnnouncementREG - GlaxoSK Capital PLC GSK PLC - Final results of outstanding Notes Tender Offer
AnnouncementREG - GSK PLC - Block listing Interim Review
AnnouncementREG - GlaxoSK Capital PLC GSK PLC - Interim results of outstanding Notes Tender Offer
AnnouncementREG - GSK PLC - GSK Update: Zejula 2L in US
AnnouncementREG - GSK PLC - Sanofi-GSK COVID booster vaccine approved by EU
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Block Listing Application
AnnouncementREG - GlaxoSK Capital PLC GSK PLC - Launch of Tender Offer for outstanding Notes
AnnouncementREG - GSK PLC - DREAMM-3 phase III trial for Blenrep
AnnouncementREG - GlaxoSK Capital PLC GSK PLC - Publication of Suppl.Prospcts
AnnouncementREG - Allianz Glbl Inv - Top 10 Holdings
AnnouncementREG - GSK PLC - IDMC recommends gepotidacin early efficacy stop
AnnouncementREG - GSK PLC - 3rd Quarter Results
AnnouncementREG - GSK PLC - GSK RSV vaccine: US FDA Priority Review
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - EMA validates MAA for cabotegravir LA for PrEP
AnnouncementREG - GSK PLC - EMA accepts GSK RSV older adult vaccine for review
AnnouncementREG - GSK PLC - GSK announces FDA meeting outcome on daprodustat
Announcement